Pro-inflammatory cytokines and Interleukin-10 modulation

Pro-inflammatory cytokines and IL-10 modulation refers to a therapeutic strategy or pharmacological effect rather than a single molecular target. This process involves the down-regulation of pro-inflammatory mediators such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which drive systemic and local inflammation, alongside the up-regulation or stabilization of Interleukin-10 (IL-10), a potent anti-inflammatory cytokine (Nature Reviews Immunology, 2017). IL-10 functions by inhibiting the synthesis of pro-inflammatory cytokines and suppressing the antigen-presenting capacity of monocytes and macrophages (PubMed, PMC3123960). This dual modulation is critical in treating chronic inflammatory conditions, autoimmune diseases, and sepsis, where an imbalance between pro- and anti-inflammatory signals leads to tissue damage (StatPearls, 2023). Various drugs, including corticosteroids, phosphodiesterase inhibitors like pentoxifylline, and specific biologics, achieve therapeutic efficacy by shifting the cytokine profile toward an anti-inflammatory state. However, because this modulation affects broad immune pathways, therapeutic interventions must be carefully managed to avoid excessive immunosuppression and increased susceptibility to infections (NIH, 2022).

Other names

Cytokine modulationPro-inflammatory/anti-inflammatory cytokine balanceRegulation of inflammatory mediatorsCytokine production inhibition

The mechanism involves the simultaneous inhibition of pro-inflammatory signaling pathways (such as NF-κB or p38 MAPK) to reduce the production of cytokines like TNF-α and IL-6, while promoting the expression or activity of the anti-inflammatory cytokine IL-10 to resolve the inflammatory cascade.